Interv Akut Kardiol. 2009;8(5):265-268

Pulmonary hypertension in chronic heart failure and options of affecting it

Martin Šurda, Hikmet Al-Hiti, Vojtěch Melenovský, Jiří Kettner, Josef Kautzner
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

Various degree of secondary pulmonary hypertension can be found in a significant number of patients with advanced heart failure. It

has been considered as an important predictor of morbidity and mortality. Currently, a variety of specific therapies is available for treatment

of idiopathic arterial hypertension – endothelin receptor blockers, phosphodiesterase 5 inhibitors and prostanoids. These drugs

influence favourably symptoms, haemodynamic parameters and prognosis. Some of them are promissing also for treatment of secondary

pulmonary hypertension. The aim of this review is to summarize current possibilities of management of pulmonary hypertension

associated with chronic heart failure.

Keywords: heart failure, pulmonary hypertension, sildenafil, endothelin, heart transplantation.

Published: November 20, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šurda M, Al-Hiti H, Melenovský V, Kettner J, Kautzner J. Pulmonary hypertension in chronic heart failure and options of affecting it. Interv Akut Kardiol. 2009;8(5):265-268.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Badesh DB, Champion HC, Gomez Sanchez MA, et al. Diagnosis and Assessment of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2009; 54: S55-S66. Go to original source... Go to PubMed...
    2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146. Go to original source... Go to PubMed...
    3. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients wich heart failure. J Am Col Cardiol 1999; 34: 1802-1806. Go to original source... Go to PubMed...
    4. Delgado F, Conde Esther, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7(6): 1011-1016. Go to original source... Go to PubMed...
    5. Klotz S, Wenzelburger F, Stypmann J, et al. Reversible Pulmonary Hypertension in Heart Transplant Candidates: To Transplant or Not to Transplant. Ann Thorac Surg 2006; 82: 1770-1773. Go to original source... Go to PubMed...
    6. Cappola T, Felker M, Linda Kao WH, et al. Pulmonary Hypertension and Risk of Death in Cardiomyopathy: Patients With Myocarditis Are at Higher Risk. Circulation 2002; 105: 1663-1668. Go to original source... Go to PubMed...
    7. Ghio S, Gavazzi A, Capana C, et al. Independent and additive prognostic value of right ventricular function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2005; 37: 183-188. Go to original source... Go to PubMed...
    8. Al-Hiti H. Heart Transplantation in Patients with Severe Pulmonary Hypertension. Chest 2007; 132(4): 582. Go to original source...
    9. Moncada S. Biology and therapeutic potential of prostacyclin. Stroke 1983; 14: 157-168. Go to original source... Go to PubMed...
    10. Montalescot G, Drobinski G, Meurin P, et al. Effects of Prostacyclin on the Pulmonary Vascular Tone and Cardiac Contractility of Patients With Pulmonary Hypertension Secondary to EndStage Heart Failure. Am J Cardiol 1998; 82: 749-755. Go to original source... Go to PubMed...
    11. Califf RM, Adams KA, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54. Go to original source... Go to PubMed...
    12. Olschwski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824. Go to original source... Go to PubMed...
    13. Sablotzki A, Hentschel T, Hofmann S, et al. Inhaled aerosolized iloprost in the evaluation of heart transplant candidates - experiences with 45 cases. J Clin Anesth 2006; 18(2): 108-113. Go to original source... Go to PubMed...
    14. von Scheidt W, Costard-Jaeckle A, Stempfle HU, et al. Prostaglandin E1 Testing in Heart Failure-associated Pulmonary Hypertension Enables Transplantation: The PROPHET Study. J Heart Lung Transplant 2006; 25: 1070-1076. Go to original source... Go to PubMed...
    15. Cowburn PJ, Cleland JG. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J 2001; 22: 1772-1784. Go to original source... Go to PubMed...
    16. Torre-Amione G, Young JB, Durand JB, et al. Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure, Circulation 2001; 103: 973-980. Go to original source... Go to PubMed...
    17. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio. net Editorial Team. Eur J Heart Fail 1999; 1: 197-200.
    18. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 2002; 8: 124-127. Go to original source... Go to PubMed...
    19. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 347-354. Go to original source... Go to PubMed...
    20. Black SM, Sanchez LS, Mata-Greenwood E, et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1051-L1057. Go to original source... Go to PubMed...
    21. Corbin JD, BBeasley A, Blount MA, et al. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005; 334: 930-938. Go to original source... Go to PubMed...
    22. Alaeddini J, Uber PA, Park MH, et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004; 94: 1475-1477. Go to original source... Go to PubMed...
    23. Al-Hiti H, Melenovsky V, Kettner J, et al. Sildenafil is more selective pulmonary vasodilator than PGE1 in patients with severe pulmonary hypertension secondary to heart failure. Chest 2008; 134: s32001. Go to original source...
    24. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127: 1647-1653. Go to original source... Go to PubMed...
    25. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780-2785. Go to original source... Go to PubMed...
    26. Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007; 31: 698-702. Go to original source... Go to PubMed...
    27. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007; 133: 689-695. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.